AstraZeneca

Healthcare

Asia Has Become ‘Epicenter’ of Prescription Drug Innovation: McKinsey

Photo via James Black/Icon Sportswire DHN/James Black/Icon Sportswire/Newscom

US firms are also staring down a multi-billion dollar patent cliff of their own, prompting a yearslong buying spree.

2 min read

Photo by SiyueSteuber via iStock

Healthcare

Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 Billion

J&J this year lost its patent exclusivity for Stelara, its longtime top-selling drug that treats psoriasis and inflammatory bowel disease.

2 min read
Photo via Cfoto/ZUMAPRESS/Newscom

Healthcare

CEO Says AstraZeneca Can ‘Absorb’ Costs of Trump-Driven US Deals

AstraZeneca is the biggest drugmaker in Britain and its £193 billion ($253 billion) market capitalization tops the London Stock Exchange.

2 min read
Photo via Image courtesy of Genmab, All rights reserved. © 2024 Genmab A/S

Healthcare

Genmab Strikes $8 Billion Deal for Cancer Treatment Maker Merus

BMO analysts said in a note Monday they were “encouraged” that Genmab’s acquisition “could start to spur broader M&A in the sector.”

2 min read

Healthcare

China’s Multibillion-Dollar US Pharma Pipeline Draws Scrutiny in Washington

Photo via Mu Yu / Xinhua News Agency/Newscom

China’s pharmaceutical sector, a minor player just years ago, has revved up into a global juggernaut faster than a Fuxing high speed train.

2 min read

Regulation

FTC Challenges Hundreds of Pharma Patents

Photo by Chemist4U via CC BY-SA 2.0

The regulator sees some patents as ploys to keep companies from developing cheaper generic versions of 20 different brand-name drugs.

2 min read

Image Credit: AstraZeneca

Healthcare

Breakthrough AstraZeneca Breast Cancer Drug Massively Reduces Disease and Fatalities in Trial

1 min read
Image Credit: iStock, Inside Creative House

Healthcare

Moderna And Pfizer Raise Vaccine Prices In Europe

1 min read
Healthcare

AstraZeneca Joins The Fight Against Rare Diseases

1 min read

Sign Up for The Daily Upside to Unlock This Article

Sharp news & analysis on finance, economics, and investing.